ST. LOUIS, TORONTO & BOSTON--(BUSINESS WIRE)--C2N Diagnostics, InterVivo Solutions, and inviCRO (“Companies”) today announced the formation of a pre-competitive consortium to develop, standardize, and validate an aged-canine model of Alzheimer’s disease (AD) progression. The multi-year collaboration is believed to be the first-of-its-kind. It will rely on the longitudinal measurement of disease-specific and clinically relevant biomarkers in canine aging. The study is modeled after the Alzheimer’s Disease Neuroimaging Initiative (ADNI) initiative in humans. The characterization of AD relevant biomarkers in a preclinical model of disease aims to create a robust and reliable method for the screening of candidate therapies that may prevent, slow, or reverse Alzheimer’s pathology and symptomology. Ultimately, the work from this collaboration intends to improve the translatability of Alzheimer’s preclinical drug development to human drug development.
